Retrospective Review of Positive Newborn Screening Results for Isovaleric Acidemia and Development of a Strategy to Improve the Efficacy of Newborn Screening in the UK.

false positive inherited metabolic disease isovaleric acidemia newborn screening

Journal

International journal of neonatal screening
ISSN: 2409-515X
Titre abrégé: Int J Neonatal Screen
Pays: Switzerland
ID NLM: 101665400

Informations de publication

Date de publication:
13 Mar 2024
Historique:
received: 23 01 2024
revised: 20 02 2024
accepted: 04 03 2024
medline: 27 3 2024
pubmed: 27 3 2024
entrez: 27 3 2024
Statut: epublish

Résumé

Since the UK commenced newborn screening for isovaleric acidemia in 2015, changes in prescribing have increased the incidence of false positive (FP) results due to pivaloylcarnitine. A review of screening results between 2015 and 2022 identified 24 true positive (TP) and 84 FP cases, with pivalate interference confirmed in 76/84. Initial C5 carnitine (C5C) did not discriminate between FP and TP with median (range) C5C of 2.9 (2.0-9.6) and 4.0 (1.8->70) µmol/L, respectively, and neither did Precision Newborn Screening via Collaborative Laboratory Integrated Reports (CLIR), which identified only 1/47 FP cases. However, among the TP cases, disease severity showed a correlation with initial C5C in 'asymptomatic' individuals (

Identifiants

pubmed: 38535128
pii: ijns10010024
doi: 10.3390/ijns10010024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Rachel S Carling (RS)

Biochemical Sciences, Synnovis, Guys & St Thomas' NHSFT, London SE1 7EH, UK.
GKT School of Medical Education, Kings College London, London WC2R 2LS, UK.

Katy Hedgethorne (K)

Biochemical Sciences, Synnovis, Guys & St Thomas' NHSFT, London SE1 7EH, UK.

Anupam Chakrapani (A)

Department of Metabolic Medicine, Great Ormond Street Hospital NHSFT, London WC1N 3JH, UK.

Patricia L Hall (PL)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.

Nick Flynn (N)

Biochemical Genetics Unit, Cambridge University Hospitals NHSFT, Cambridge CB2 0QQ, UK.

Toby Greenfield (T)

Portsmouth Hospitals Trust, Portsmouth PO6 3LY, UK.

Stuart J Moat (SJ)

Department of Medical Biochemistry, Immunology & Toxicology, University Hospital Wales, Cardiff CF14 4XW, UK.
School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Joshua Ssali (J)

South West Thames Newborn Screening, Epsom & St Helier Hospitals, Carshalton SM5 1AA, UK.

Lynette Shakespeare (L)

Clinical Chemistry, Sheffield Children's NHSFT, Sheffield S10 2TH, UK.

Nazia Taj (N)

Department of Clinical Biochemistry, Oxford University Hospitals NHSFT, Oxford OX3 9DU, UK.

Teresa H Y Wu (THY)

Willink Biochemical Genetics Laboratory, Genomic Medicine, Manchester University NHSFT, Manchester M13 9WL, UK.

Mark Anderson (M)

Great North Children's Hospital, Newcastle Upon Tyne Hospitals NHSFT, Newcastle NE1 4LP, UK.

Arunabha Ghosh (A)

Willink Biochemical Genetics Unit, Manchester University NHSFT, Manchester M13 9WL, UK.

Hugh Lemonde (H)

Department of Paediatric Metabolic Medicine, Evelina London Children's Hospital, Guys & St Thomas' NHSFT, London SE1 7EH, UK.

Germaine Pierre (G)

University Hospitals Bristol and Weston NHSFT, Bristol BS1 3NU, UK.

Mark Sharrard (M)

Paediatric Medicine, Sheffield Children's NHSFT, Sheffield S10 2TH, UK.

Sreevidya Sreekantam (S)

Birmingham Women's and Children's Hospital, Birmingham B4 6NH, UK.

James R Bonham (JR)

Clinical Chemistry, Sheffield Children's NHSFT, Sheffield S10 2TH, UK.

Classifications MeSH